Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
- None.
- None.
Insights
The approval of Venus Bliss MAX by the State of Israel Ministry of Health is a strategic milestone for Venus Concept, potentially opening up revenue streams within the Israeli market. Israel is known for its advanced medical technologies and a strong aesthetic industry. The introduction of a new medical device like Venus Bliss MAX could cater to an already tech-savvy and health-conscious consumer base.
From a market perspective, this approval could signal an expansion strategy by Venus Concept, which investors might view positively. The aesthetic technology market is competitive and successful entry into new markets is key for growth. This approval could lead to increased sales and a stronger market position in the Middle East, complementing the company's existing direct sales efforts and R&D investments in the region.
The broader impact on the stock market will likely depend on the company's ability to capitalize on this approval. This includes effective marketing, supply chain management and post-market support. If Venus Concept leverages this opportunity well, it could see an uptick in its stock price as investors recognize the potential for growth.
The regulatory approval of a medical device like the Venus Bliss MAX is a complex and significant process. The State of Israel Ministry of Health's approval indicates that the device meets safety and efficacy standards required for use in medical aesthetics. This is a positive sign for stakeholders concerned about product quality and compliance.
For Venus Concept, navigating different international regulatory landscapes is essential for global distribution. The clearance by the Israeli Ministry of Health not only opens the door for the Venus Bliss MAX in Israel but also serves as a precedent for potential approvals in other countries with similar regulatory requirements. This could streamline the process for future international expansions.
However, it's important to note that such approvals do not guarantee market success. The company must still effectively manage the product launch, training for practitioners and patient outreach to ensure the device's benefits are fully realized in the new market.
The approval of Venus Bliss MAX in Israel is a noteworthy development for Venus Concept from a financial standpoint. The company's ability to grow its product offerings in new jurisdictions is important for its revenue diversification and long-term growth strategy. Israel represents a market with high potential due to its strong aesthetic industry and technological advancements.
Analyzing the potential financial impact involves looking at the company's past performance with similar product launches. If the Venus Bliss MAX follows the trend of successful launches in other regions, it could contribute positively to the company's top-line growth. Additionally, the direct sales model in Israel could result in higher profit margins compared to distribution through third parties.
In the short term, the announcement may lead to positive investor sentiment, potentially boosting the stock price. In the long term, sustained revenue from the Israeli market could contribute to the company's overall financial health. However, investors should also consider the costs associated with market entry, including marketing, sales force expansion and post-sales support, which could affect profit margins.
TORONTO, April 08, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received approval for the Venus Bliss MAX from the State of Israel Ministry of Health. The Venus Bliss MAX was first launched commercially in the United States in Q1 2022 after FDA 510(k) clearance and offered internationally in approved jurisdictions.
The Venus Bliss MAX offers three advanced technologies in one platform: diode laser applicators, (MP)2 applicator that combines Multi-Polar Radio Frequency and Pulsed Electro Magnetic Fields with advanced VariPulse™ technology and the Company’s FlexMax EMS applicators. This advanced three-in-one platform enables practitioners to offer treatments for non-invasive lipolysis of the abdomen, flanks, back, and thighs, relief of muscle aches and pain, relief of muscle spasms, improvement in blood circulation, reduction in the appearance of cellulite and for muscle conditioning to stimulate healthy muscles.
“The Venus Bliss MAX has been well received internationally, and we look forward to bringing our comprehensive all-in-one platform to the Israeli aesthetic service providers,” said Dr. Hemanth Varghese, President and Chief Operating Officer of Venus Concept. “Israel is an important market, with significant history in the aesthetic industry, in which we not only continue to grow our direct sales presence but also invest in new innovative products through our local research & development team.”
Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. In some cases, you can identify these statements by words such as such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “should,” “could,” “estimates,” “predicts,” “potential,” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, and projections about our business, and the industry in which the Company operates and management's beliefs and assumptions and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under Part II Item 1A-“Risk Factors” in our Quarterly Reports on Form 10-Q and Part I Item 1A-“Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this communication. Unless required by law, the Company does not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise.
About Venus Concept
Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 12 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa Pro, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.
FAQ
What technology does Venus Bliss MAX offer?
Where was Venus Bliss MAX first launched commercially?
What treatments can practitioners offer with Venus Bliss MAX?
Who is the President and Chief Operating Officer of Venus Concept?
Which market did Venus Concept recently expand into with Venus Bliss MAX approval?
